NEW YORK – Based on the results of a study published in the Annals of Oncology in April, researchers suggested that testing metastatic breast cancer patients for kinase fusions, particularly those who become resistant to endocrine therapy, may identify targetable biomarkers and open up additional treatment opportunities.